Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 17/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 16/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 16/20 | 0.57 |
| ▸ | MINK1 | Q8N4C8 | 14/20 | 0.57 |
| ▸ | PRKD2 | Q9BZL6 | 13/20 | 0.57 |
| ▸ | CSNK1A1 | P48729 | 13/20 | 0.57 |
| ▸ | GSK3B | P49841 | 12/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 11/20 | 0.57 |
| ▸ | CSNK1G2 | P78368 | 9/20 | 0.57 |
| ▸ | CSNK1G3 | Q9Y6M4 | 9/20 | 0.57 |
| ▸ | TAOK1 | Q7L7X3 | 9/20 | 0.57 |
| ▸ | CSNK1G1 | Q9HCP0 | 5/20 | 0.57 |
| ▸ | GSK3A | P49840 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.57 |
| ▸ | CLK2 | P49760 | 1/20 | 0.57 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.57 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 17/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744982 | 1.00 | MAP4K4 (0.57) | MAP4K4PRKD3MAPK9MINK1PRKD2 | |
| SCHEMBL12154511 | 1.00 | MAP4K4 (0.57) | MAP4K4PRKD3MAPK9MINK1PRKD2 | |
| SCHEMBL12154523 | 0.92 | PRKD3 (0.55) | MAP4K4PRKD3MAPK9MINK1PRKD2 | |
| SCHEMBL2746062 | 0.92 | PRKD3 (0.55) | MAP4K4PRKD3MAPK9MINK1PRKD2 | |
| SCHEMBL2746065 | 0.92 | PRKD3 (0.55) | MAP4K4PRKD3MAPK9MINK1PRKD2 | |
| SCHEMBL12023567 | 0.88 | PRKD3 (0.73) | MAP4K4PRKD3MAPK9MINK1PRKD2 | |
| SCHEMBL3818285 | 0.85 | MAP4K4 (0.77) | MAP4K4PRKD3MAPK9MINK1PRKD2 | |
| Hydrochloric Acid SCHEMBL2745296 | 0.85 | MAP4K4 (0.76) | MAP4K4PRKD3MAPK9MINK1PRKD2 | |
| SCHEMBL2745547 | 0.84 | MAPK8 (0.51) | MAP4K4PRKD3MAPK9MINK1PRKD2 | |
| SCHEMBL2745543 | 0.84 | MAPK8 (0.51) | MAP4K4PRKD3MAPK9MINK1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2258704-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ArQule, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ARQULE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| EP-1809636-A1 | SYNTHESIS OF IMIDAZOOXAZOLE AND IMIDAZOTHIAZOLE INHIBITORS OF P38 MAP KINASE | ARQULE, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006044869-A1 | SYNTHESIS OF IMIDAZOOXAZOLE AND IMIDAZOTHIAZOLE INHIBITORS OF P38 MAP KINASE | ARQULE, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK8, MAPK7 | MAP4K4 44/4885PRKD3 541/4885MAPK9 31/4885 |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | MAPK1, MAPK14, MAPK15 | MAP4K4 38/4885PRKD3 607/4885MAPK9 39/4885 |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK7, MAPK8 | MAP4K4 43/4885PRKD3 507/4885MAPK9 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.